ARCA biopharma, Inc. and Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors of ARCA have mutually agreed to conclude Dr. Bristow's employment and service as a director, effective April 3, 2024. In connection with Dr. Bristow's separation, ARCA and Dr. Bristow entered into a separation agreement on April 3, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.325 USD | +0.45% | -4.90% | +94.12% |
Apr. 25 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+94.12% | 48.02M | |
+18.47% | 125B | |
+14.38% | 109B | |
-2.60% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.39% | 16.64B | |
+0.05% | 13.45B | |
+23.28% | 11.32B |
- Stock Market
- Equities
- ABIO Stock
- News ARCA biopharma, Inc.
- ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer